🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
55.75
-0.60 (-1.06%)
At close: Nov 20, 2026, 4:00 PM EST
55.95
+0.20 (0.36%)
After-hours: Nov 20, 2026, 7:43 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Breast reconstruction growth is accelerating, supported by expanded sales coverage and improving reimbursement; U.S. penetration is ~15% of a $700 million opportunity. Prostate targeting is planned for early 2027, while margin initiatives are expected to take time to benefit results.

Mike Sarcone
Analyst, Jefferies

We can kick it off. Good afternoon, and welcome to the Jefferies Global Healthcare Conference in London. My name is Mike Sarcone. I am an analyst on the U.S. Medical Supplies and Devices team, and this is the session for AxoGen. And with us from the company, we have Mike Dale, CEO, and Lindsey Hartley, CFO. Mike, Lindsey, thank you for joining us.

Mike Dale
CEO, AxoGen

Our pleasure.

Lindsey Hartley
CFO, AxoGen

Thank you.

Mike Sarcone
Analyst, Jefferies

I guess just to kick off, Mike, for those in the audience who are less familiar with the story, maybe can you give us a brief overview of the company's mission and value proposition in the marketplace? Then just to level set the conversation, talk about key strategic priorities as we exit this year and head into 2027.

Mike Dale
CEO, AxoGen

Certainly. AxoGen is dedicated to peripheral nerve restoration. Our literal mission is to restore health and improve quality of life by making the restoration of peripheral nerve function an expected standard of care. Starting with that really begets and describes our work every day. Now, your peripheral nerve function, for those who just haven't thought about it, because it's something you take for granted, is your sensory function and your motor function. Your whole body is essentially reflecting those functions. When those are disturbed through either disease or injury or iatrogenic side effect interventions for treating some other problem, for the most part, those defects are not treated. There's a lot of reason for that, historically.

One, a lack of treatment options that were available, or only the ability to use an autograft, basically harvesting a nerve from somewhere else on the body and using that as a substitute. This is a situation which crosses all types of healthcare situations and different specialties. AxoGen, in terms of our work product, is about making the restoration of those functions an expectation. Strategically, the priorities we've set for doing that were the product of a traditional strategic planning process exercise to understand how we could make progress on that in the most effective, efficient way, which is what obviously those processes are about. For us, as a public company, it was about setting a platform of expectations and doing so very publicly for all stakeholders.

One was growth, and that was, we believed that looking at the opportunities we had in front of us, that we could guide to 15%-20% growth, and that we could incrementally drive that growth while also demonstrating operational leverage incrementally year to year over four. So that was the overarching landscape. In terms of how we would achieve that, we focused on a second priority, which was market development in certain focused areas. Our history was in a marketplace we call extremities. Most of that is emergent trauma. As we would invest in that, we also focused on oncological procedures where they're planned procedures and the patient is also part of the equation. That included breast Resensation, so restoring peripheral nerve function sensation post-mastectomy as part of the reconstruction process. Secondly, we would investigate and evaluate prostate.

The third priority that we focused on was, and we were very public about in terms of how we would do so, was simply expanding footprint. The organization that the company had when I first joined was small relative to the number of service sites as well as to the number of procedures. The very simple effort was to build an organization that would allow for proper attendance and coverage of the physical sites, as well as the training that accompanies these procedures. The fourth was commercial excellence, and expressly what we were talking about there is that one of the challenges in our opportunity is not that there isn't a lot of need that we could address, it's that it's very diverse in its manifestation. So the market's very heterogeneous.

Unlike cardiology or cardiac surgery, where you have a handful of people that you need to focus on holistically, with regards to nerves, it ranges everything from a trauma surgeon who is involved, to across 20 different specialties, if I count them all. Different care pathways, different physician societies, and so on. We needed to identify and develop business models for that purpose. The next element was to drive towards standard of care. Because, as we said, it is part of our mission, there is no expectation to treat nerve injuries. To do that, we needed to drive evidence, societal advocacy, and then coverage and payment, because they are both interdependent. Finally, innovation. Invest in the future to make these procedures less technical and more adoptable.

Mike Sarcone
Analyst, Jefferies

Okay. Very helpful overview. Thanks, Mike. I do want to hit on a bunch of different topics, but I wanted to start on breast reconstruction because we have seen some really significant growth acceleration there. I think it was over 50% in 2Q, and that accelerated to over 60% year-over-year growth in 3Q. It seems like momentum is building. I guess, can you talk about what you are seeing in that market and what is driving that meaningful acceleration?

Mike Dale
CEO, AxoGen

Certainly. A number of basic factors consistent with what I just shared. Number one was we have expanded the physical footprint of the sales organization. About two and a half years ago, we had about 10 people. Today, we have 31 people. Ultimately, our target is to get to 60 people, which would give us a ratio of one representative to 20 accounts, which is the total physical account TAM in terms of service sites. These individuals are crucial because they are the ones who obviously make the calls, they, on a consultative basis, develop awareness of the opportunities to restore sensation, and they help conduct and arrange all the logistics associated with the training. Because the training involves both the oncological surgeon as well as a plastic surgeon who does the actual nerve repair, and they work as a team.

In order to bring this forward, you need to have a sales force. We very simply, we have expanded that. The value proposition is quite powerful for these procedures, in particular for breasts, because you are introducing an opportunity to mitigate the consequence of a cancer surgery, which leaves you without any feeling. As part of the reconstruction process, what we are offering here is another step, not just aesthetically, but functionally, to restore that patient's level of peripheral nerve function. As we train surgeons and as they adopt it, what we are finding is these surgeons do not stop procedures. They continue to do so, and it becomes part of their repertoire, part of what they consider standard of care for them.

As you do one surgeon, as you might imagine, the person who sits down the hallway who has not yet been trained soon wants to do the same thing because it begs the question from an equipoise standpoint, how could you not offer this if you're doing it with one surgeon as part of your cancer repertoire in a hospital and not another? This builds on itself. This reflects in terms of same-store sales. You have one surgeon, they start doing the procedure, then another surgeon adds on to that. As this is happening, what's also happening is in the care pathway, the referring physicians are now very strongly moving their patients towards those individuals.

Within a community in a metropolitan area, once you get one center going, then the other center across the street wants to participate as well because, as you might imagine, it becomes quite difficult to, as part of your hospital services, to do these procedures and not offer the chance to do a complete reconstruction. Overlaying all of this is coverage and reimbursement has advanced over those years. You put this all together, then the whole process now is much more efficient and effective in terms of being indicated for treatment and then offering the treatment. Those barriers are come down. Physicians are less reticent about adopting because they know that's out of the way. All this is building on itself, and ergo, why we have high growth. Expect to see that for years to come.

Mike Sarcone
Analyst, Jefferies

Okay. That kind of leads to the next question. I was going to ask about how you think about growth runways. Even in the U.S., where do you estimate we are in terms of penetration as we exit this year? Is OUS an addressable opportunity as well at some point?

Mike Dale
CEO, AxoGen

I'll start with the first question.

Mike Sarcone
Analyst, Jefferies

Sure.

Mike Dale
CEO, AxoGen

From a penetration standpoint, we are approximately 15% today. In terms of the opportunity as we see it, we see it as effectively a TAM that is fully addressable. To that end, the $700 million opportunity as we see it is a very tangible opportunity. When you look at the accounts we have left to open as we expand the sales force, we believe that all the drivers I previously described will perpetuate and continue for years to come. This should be a very handsome business, adding great quality of life to individuals who have otherwise been affected by cancer, and obviously become a very important part of our business. In terms of OUS, absolutely. This originally part of our equation was to go OUS. We ended up not investing the time and resources in that as we got going.

There were just from a prioritization standpoint, things we needed to do and finish to get started in the U.S. But this year, we are finally taking the step, as we go into the new year, to dedicate a small team to developing the OUS markets in earnest. Breast and prostate are already very high in the list, followed by Nerve Tape. We just need to complete the regulatory process for that.

Mike Sarcone
Analyst, Jefferies

Oh, okay. Interesting. That is very helpful. You also highlighted improving reimbursement backdrop as another uptake factor here for breast. We did recently see Aetna come out with breast reconstruction coverage. I guess, A, how meaningful is that for you as we kind of get into 2027? The second part of the question is, you are seeing some of these coverage decisions absent any Level 1 evidence. Just given there is a meaningful value proposition here clinically, can you continue to progress on coverage wins, absent Level 1 evidence?

Mike Dale
CEO, AxoGen

Yes, we believe so. Again, it is unique as a value proposition insofar as most of the time in med tech, when you are introducing something, there is a totally appropriate balance of, well, how much benefit do you provide relative to your risk as compared to the alternative standards of care that might exist? In nerve care, the patient's risk factor is essentially the reason why they are presenting in the first place, which is usually injury, a trauma of some sort, and/or an intervention such as a cancer procedure. The power of this value proposition is that we are able to provide a very high probability of some level of mitigation of that consequence, but we introduce zero risk effectively, because the product itself is benign. When you look at that and you think about that, as value propositions go, it does not get much stronger than that.

Mike Sarcone
Analyst, Jefferies

Yeah, I remember when I first started digging into the MAUDE database looking for AxoGen, like over 17 years, I found two mentions, and it was for mislabeled packaging and product was broken inside the packaging. No adverse events that I was able to find. I guess we can loop in Lindsey here. I guess, we've recently seen some pressure on gross margin for what I'd argue are good reasons, faster than expected breast reconstruction growth. But I guess, can you kind of give us an overview of the factors that are at play on the gross margin side and maybe some of the efforts you're taking to offset the headwinds?

Lindsey Hartley
CFO, AxoGen

Yeah, absolutely. So, like you mentioned, because of our acceleration in our breast business, we are experiencing some, sorry, headwinds against our gross margin, some pressure there. In 3Q, we adjusted our production plans in order to accommodate producing more long grafts, and that comes at a higher cost. So, we have guided that in 4Q, we expect to see some compression in gross margin and to expect 2027 to be consistent with 2026. Things we have underway in order to kind of offset some of that is pricing initiatives that we're going through right now, to put in effect in April 1, but they will take time to go through as a large percentage of our customers are on contracts. So that would take some time to flow through. We also have some yield initiatives underway in order to get more long grafts from every donor that we process.

So those are underway. Some we have regulatory requirements, quality requirements that we'll have to go through and prove out.

Those will take time, but will benefit us in the longer term.

Mike Sarcone
Analyst, Jefferies

Okay. You have talked about gross margin because of these factors for 2027 being roughly flat-ish—

Lindsey Hartley
CFO, AxoGen

Yes

Mike Sarcone
Analyst, Jefferies

—versus 2026. I guess when you look out as you start to see benefit from some of these initiatives, like when could we start to see gross margin move the other way?

Lindsey Hartley
CFO, AxoGen

Yeah, I would say probably late 2027 and into 2028 is when we should start to see some of the initiatives, particularly price.

I think then yield probably later 2028 and ongoing.

Mike Sarcone
Analyst, Jefferies

Okay.

And I believe when you announced the BioCircuit deal, you also said that was margin accretive as well.

Lindsey Hartley
CFO, AxoGen

Yes.

Mike Sarcone
Analyst, Jefferies

Could we start to see some, or I guess, benefits from that as we work through 2027 and you ramp?

Lindsey Hartley
CFO, AxoGen

We can, yes.

Mike Sarcone
Analyst, Jefferies

Okay.

Lindsey Hartley
CFO, AxoGen

It produces a gross margin of, when we acquired it, about 80% and is price comparable and gross margin comparable to our other nerve repair algorithm products. As we move into next year, it also is a consideration for price.

We do plan on taking some price on that product, so it will help in the longer run.

Mike Sarcone
Analyst, Jefferies

Okay, great. Wanted to move to prostate, pretty exciting. You're going to start targeting that market in early 2027. You recently just hosted a nice prostate event with a doctor who participated in the pilot trial. I guess, initially with the market sizing, you've talked about $750 million. Can you talk about, Mike, what are the use cases that are baked into there? I think, it may skew conservative as there are some other potential use cases that aren't included. Maybe you can highlight those.

Mike Dale
CEO, AxoGen

Sure. The basic use cases in prostate surgery are for all prostate procedures, whether you need to regraft nerves or not, protection is a consideration. Protection, it really involves literally that. You're protecting the nerves that remain so that they have the best opportunity to heal post-procedure. Even if they've been preserved, there's still a lot of trauma by virtue of the removal of the prostate from the capsule. That's for every procedure, and in principle, protection could be part of the physician's activities. The other elements is with respect to nerve grafting. In about 40% of the cases, and this is general average, one or both nerves are required to be removed because of where the cancer is located in the prostate.

When that happens, there is a definitive loss of function that's pretty well established and very well characterized, and this leads to erectile dysfunction and incontinence. The value proposition here is just like in the other areas I've discussed, it's very powerful. You can introduce grafting, therefore it represents an opportunity to mitigate those deleterious outcomes without adding any risk whatsoever. From a procedure standpoint and technical standpoint, the techniques are very teachable, and they add de minimis amounts of time to the procedure. Surgeons are very excited about this, because despite their refinements and techniques over many years with the robot, there's only so much you can do through technique. This is a chance to provide a definitive, demonstrable improvement in outcomes of these procedures for patients.

For the patient, as you might imagine, they are highly motivated when they hear about this, because one of the biggest reasons why men do not even get tested, much less move forward with treatment, is fear of the side effects. In our work that we have done with physicians, with the facilities, and the patients, we see extremely strong demand.

Mike Sarcone
Analyst, Jefferies

Okay. Could this theoretically also bring patients off the sidelines who may be on active surveillance or who may have put off surgery previously because of the high risk of those adverse outcomes?

Mike Dale
CEO, AxoGen

I think in the future, yes. I think out of the gate, I think the basic element, as you might guess, is just making sure that people are even aware that this is available.

Mike Sarcone
Analyst, Jefferies

Just to be clear, something like bringing patients in from the sidelines, that is not baked into the current TAM?

Mike Dale
CEO, AxoGen

No.

Mike Sarcone
Analyst, Jefferies

So that will be upside?

Mike Dale
CEO, AxoGen

The current TAM is literally from the recorded statistics in terms of unilateral or bilateral loss of nerves.

Mike Sarcone
Analyst, Jefferies

Got it. Okay. Helpful. I did want to touch on addressability. You have commented that out of all the markets you are in or targeting, urology is the most addressable. So maybe can you expound on what that means and why?

Mike Dale
CEO, AxoGen

Sure. Part of it just is, there is both emotive and then there is just logistics. Let us start with logistics. Unlike every other nerve procedure that we do, where there might be as many as two to as many as 10 different specialties we might need to interact with in order to make nerve care part of the equation, in prostate cancer, there is only one person. There is the prostate surgeon. So there is no partner needed. The training is very simple because they are already trained in terms of these micro movements and techniques. So they become very fast and all very quick just through conversations. It takes very little time. So that in itself makes the selling process binary and very simple.

And then with regards to the patient, as you might imagine, if you ask someone, "Would you like a chance to mitigate the consequences and side effects?" They're going to say yes.

Mike Sarcone
Analyst, Jefferies

Yep. Yeah, that makes sense. I guess when you think about that, and we're all going to start thinking about what makes sense from a ramp standpoint, right, as we get into 2027. Breast reconstruction is growing very rapidly. You've been commercializing that since 2018. Is it fair to look at that as an adoption analog?

Mike Dale
CEO, AxoGen

In more recent years, not going back through history, because there was a lot of reasons why the company didn't move forward and expand the sales force. But yes, it should be at least similar to a recent experience, on the assumption that we're able to overcome payment barriers. Other than that, from a selling standpoint, training standpoint, as I just described, this is a simpler process. But the way we're going to approach that is we're going to test the hypothesis. The hypothesis specifically is driven by, we have 10 sales reps across the United States. We're going to have assumed sales cycles, assumed adoption rates. Based upon those assumptions, we hope to learn as the year progresses, how tight the bell curve is on those logistics assumptions in terms of customer creation and retention.

Based upon that, we'll adapt in one way or another, positively or negatively.

Mike Sarcone
Analyst, Jefferies

Got it. I guess, let's just assume this does hit your bull case scenario or kind of enthusiastic expectations. Are there any concerns or limitations from a manufacturing capacity standpoint, or do you have the capacity you need to address the market?

Mike Dale
CEO, AxoGen

In terms of tissue procurement, there's sufficient capacity. We still have to plan for that, and we have to execute on that and build to that, but that's what we're already planning for.

Mike Sarcone
Analyst, Jefferies

Got it. Just on the reimbursement side, you've talked about that being the biggest unknown, though we don't need that to address the market, at least initially. We have some explicit non-coverage decisions from some payers. Can you talk about why they have those and why maybe that's not kind of based on apples to apples studies versus where we are today?

Mike Dale
CEO, AxoGen

Sure. More than 20 years ago, before the robots were part of the equation, these procedures were done open. They were quite morbid, with a lot of side effects. But people, nonetheless, are always trying to innovate. One of the ideas was, as part of this procedure, maybe we can restore the nerves that we remove. They did that through taking sural nerves, which is a nerve from the back of your leg, of the patient, taking those, harvesting those, and then using those to then regraft. They set a study for themselves that had a hurdle rate for success against baseline of 50%. The study, when it was completed, only had a success rate of 30%. So that negative study led to a negative coverage decision saying that nerve grafting does not work.

Now, using sural nerves, which are not ideal, and a very gross, morbid procedure which had many different confounding factors in terms of the potential outcomes, actually wasn't a bad study when you thought about it, but just unfortunate statistics that were drawn from it. While it's apples to oranges, nonetheless, that negative policy coverage decision exists. For us to have that removed will require us to conduct ultimately a controlled study. That will probably take about three years.

Mike Sarcone
Analyst, Jefferies

Okay. Only a minute left. Was hoping to have a little more time, but BioCircuit deal, September you announced a pretty nice acquisition. I guess, can you just kind of quickly recap that deal and just tell us what that does for you from a strategic standpoint?

Mike Dale
CEO, AxoGen

Sure. Well, our whole world, despite which clinical application I'm talking about, is about taking two spaghetti noodles and putting them together. That's a nerve repair. That's what we do. Right now, up until BioCircuit, the way that's done is through microsuturing. So we spend all of our time teaching people how to sew, and using parts of our algorithm to facilitate that sewing so that these nerves stay together and they heal properly. BioCircuit is, I know the word revolution gets used over, but it's an amazingly elegant new standard of care for that purpose. So it's a product that's a small rectangular piece of tissue that's biocompatible, that has small tiny rows of micro hooks in them that you literally take the two nerves, you place them on top of that, and you roll it together.

It's extremely simple, and it's very fast, and it's mechanically more effective.

Mike Sarcone
Analyst, Jefferies

I guess last one, I know we're at time. That should help you improve the adoption. I mean, how would you characterize how big a deal, kind of the requirement to no microsutures is when you're trying to get new surgeons to adopt this?

Mike Dale
CEO, AxoGen

It's a very big deal.

Mike Sarcone
Analyst, Jefferies

Okay.

Mike Dale
CEO, AxoGen

Yeah. Sewing is still going to be part of the landscape because the use case isn't for every single situation. But for the majority of situations, it actually begs the question, why wouldn't you use a more mechanically more effective means that's also quicker and faster?

There's also advantageous reimbursement in many parts of the nerve repair as well to use it for both the facility as well as the physician to encourage faster procedures and better outcomes.

Mike Sarcone
Analyst, Jefferies

Okay, great. Well, we are at time. So, Mike, Lindsey, thank you very much.

Lindsey Hartley
CFO, AxoGen

Thank you.